ES3041328T3 - Crystal forms of glp-1r agonists and uses thereof - Google Patents
Crystal forms of glp-1r agonists and uses thereofInfo
- Publication number
- ES3041328T3 ES3041328T3 ES21798552T ES21798552T ES3041328T3 ES 3041328 T3 ES3041328 T3 ES 3041328T3 ES 21798552 T ES21798552 T ES 21798552T ES 21798552 T ES21798552 T ES 21798552T ES 3041328 T3 ES3041328 T3 ES 3041328T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- crystalline form
- peaks
- disease
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020120814 | 2020-10-14 | ||
| PCT/CN2021/123387 WO2022078352A1 (en) | 2020-10-14 | 2021-10-13 | Crystal forms of glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3041328T3 true ES3041328T3 (en) | 2025-11-11 |
Family
ID=78401981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21798552T Active ES3041328T3 (en) | 2020-10-14 | 2021-10-13 | Crystal forms of glp-1r agonists and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230382899A1 (enExample) |
| EP (1) | EP4228753B1 (enExample) |
| JP (1) | JP7769695B2 (enExample) |
| CN (1) | CN116710446B (enExample) |
| AU (1) | AU2021359493A1 (enExample) |
| CA (1) | CA3195264A1 (enExample) |
| ES (1) | ES3041328T3 (enExample) |
| TW (1) | TW202227421A (enExample) |
| WO (1) | WO2022078352A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3010351T3 (en) * | 2019-12-02 | 2025-04-02 | Hyundai Pharm Co Ltd | Glp-1 receptor agonist |
| AU2022349020A1 (en) | 2021-09-27 | 2024-05-09 | Terns Pharmaceuticals, Inc. | Benzimidazole carboxylic acids as glp-1r agonists |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| JP2025523988A (ja) * | 2022-07-18 | 2025-07-25 | 徳睿智薬（蘇州）新薬研発有限公司 | Ｇｌｐ－１ｒアゴニストの結晶多形物並びにその製造方法及び使用 |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP5382952B2 (ja) | 2008-03-07 | 2014-01-08 | トランス テック ファーマ，インコーポレイテッド | 糖尿病の治療のためのオキサジアゾアントラセン化合物 |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CN110325530B (zh) | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| PL3806855T3 (pl) | 2018-06-15 | 2023-07-24 | Pfizer Inc. | Agoniści receptora GLP-1 oraz ich zastosowania |
| EP3883928A4 (en) * | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| PH12021552557A1 (en) | 2019-04-12 | 2022-07-04 | Qilu Regor Therapeutics Inc | Glp-1r agonists and uses thereof |
| US10954221B2 (en) * | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
-
2021
- 2021-10-13 JP JP2023523059A patent/JP7769695B2/ja active Active
- 2021-10-13 ES ES21798552T patent/ES3041328T3/es active Active
- 2021-10-13 AU AU2021359493A patent/AU2021359493A1/en active Pending
- 2021-10-13 EP EP21798552.2A patent/EP4228753B1/en active Active
- 2021-10-13 CN CN202180082321.9A patent/CN116710446B/zh active Active
- 2021-10-13 TW TW110138006A patent/TW202227421A/zh unknown
- 2021-10-13 CA CA3195264A patent/CA3195264A1/en active Pending
- 2021-10-13 US US18/031,380 patent/US20230382899A1/en active Pending
- 2021-10-13 WO PCT/CN2021/123387 patent/WO2022078352A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW202227421A (zh) | 2022-07-16 |
| CA3195264A1 (en) | 2022-04-21 |
| WO2022078352A1 (en) | 2022-04-21 |
| US20230382899A1 (en) | 2023-11-30 |
| EP4228753C0 (en) | 2025-07-30 |
| CN116710446B (zh) | 2024-10-18 |
| EP4228753B1 (en) | 2025-07-30 |
| EP4228753A1 (en) | 2023-08-23 |
| AU2021359493A1 (en) | 2023-06-15 |
| JP2023546125A (ja) | 2023-11-01 |
| JP7769695B2 (ja) | 2025-11-13 |
| CN116710446A (zh) | 2023-09-05 |
| AU2021359493A9 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3041328T3 (en) | Crystal forms of glp-1r agonists and uses thereof | |
| ES2985435T3 (es) | Formas salinas y cristalinas de agonistas de GLP-1R y sus usos | |
| ES2934789T3 (es) | Agonistas del receptor glp-1 y usos del mismo | |
| US10450301B2 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| US12459923B2 (en) | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| AU2023224854A1 (en) | Compounds as glp-1r agonists | |
| US11466033B2 (en) | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors | |
| BR112020025701A2 (pt) | Processo de produção e intermediários para um composto de pirrolo[2,3-d]pirimidina e seu uso | |
| WO2021244634A1 (zh) | 咪唑并吡啶类化合物及其用途 | |
| CN111315758B (zh) | 短肽季铵盐化合物及其用途 | |
| HK40089377A (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40089377B (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40087545B (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| HK40087545A (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| CN104926706B (zh) | 六氢并环戊二烯衍生物的盐及其制备方法和应用 | |
| CN109942583B (zh) | 芳基取代的氨基四氢吡喃类化合物及其用途 | |
| TW202540152A (zh) | 具有經修飾之離胺酸殘基之雜合肽化合物 | |
| CN117813090A (zh) | 用于靶向pd-l1的方法和组合物 | |
| CN109721555A (zh) | 酰化哌嗪类化合物及其用途 |